Wednesday: Congressional Hearing Looks at Obama Administration's Drug War Policies

The U.S. House Domestic Policy Subcommittee, chaired by Rep. Dennis
Kucinich (D-OH), will hold a hearing Wednesday morning on the White
House's drug war budget and forthcoming 2010 National Drug Control
Strategy. The Director of the White House Office of National Drug
Control Policy (also known as the drug czar), Gil Kerlikowske, and the
executive director of the anti-drug-war Drug Policy Alliance, Ethan
Nadelmann, will both be testifying.

Mr. Nadelmann testimony will focus on:

• The drug war's flawed performance measures;
• The lop-sided ratio between supply and demand spending in the national drug budget;
• The lack of innovation in the drug czar's proposed strategies;
• The Administration's failure to adequately evaluate drug policies.

The hearing comes in the wake of significant drug policy reforms
under the Obama Administration, including a directive urging federal
law enforcement agencies to stop arresting medical marijuana patients
and caregivers in compliance with their state's medical marijuana law,
and the repeal of the two decade old federal syringe funding ban, which
prohibited states from funding syringe exchange programs with federal
money to prevent the spread of HIV/AIDS and hepatitis C. Additionally,
a few weeks ago a White House backed bi-partisan bill reforming the
crack/powder cocaine sentencing disparity passed the U.S. Senate
unanimously.

The Administration's drug war budget, however, is still focused
overwhelmingly on failed supply side policies and ignores important
harm reduction measures. Director Kerlikowske told the Wall Street
Journal last year that he doesn't like to use the term "war on drugs"
because "[w]e're not at war with people in this country." Yet 64% of
their budget - virtually the same as under the Bush Administration -
focuses on largely futile interdiction efforts as well as arresting,
prosecuting and incarcerating extraordinary numbers of people. Only 36%
is earmarked for demand reduction. The budget also ignores life-saving
harm reduction measures such as naloxone-distribution and heroin
assisted treatment, widely viewed around the world as a necessary part
of any balanced, evidenced based drug strategy.

"Congress and the Obama administration have broken with the costly
and failed drug war strategies of the past in some important ways,"
said Ethan Nadelmann, executive director of the Drug Policy Alliance.
"But the continuing emphasis on interdiction and law enforcement in the
federal drug war budget suggest that ONDCP is far more wedded to the
failures of the past than to any new vision for the future. I urge this
committee to hold ONDCP and federal drug policy accountable to new
criteria that focus on reductions in the death, disease, crime and
suffering associated with both drugs and drug prohibition."

What: Congressional hearing titled, "ONDCP's Fiscal Year 2011 National Drug Control Budget: Are We Still Funding a War on Drugs?"

When: 10:00AM, Wednesday, April 14th.

Where: 2154 Rayburn HOB